91results about How to "Adequately prevented" patented technology

A method is disclosed of controlling a user interface device for displaying on a display screen a plurality of objects, and for enabling a user to perform an input action by touching the display screen with the user's finger. This method includes: upon the user's touch to the display screen at a region of one of the plurality of objects being displayed, selecting the one object as a zoom target; upon an event occurring in which an intensity of the finger's touch on the display screen exceeds a predetermined threshold, determining a magnification ratio of the zoom target or a change rate of the magnification ratio, based on the intensity of the finger's touch; and zooming in the zoom target on the display screen with the determined magnification ratio or the determined change rate.

A method is disclosed of controlling a user interface device for displaying on a display screen a plurality of objects, and for enabling a user to perform an input action by touching the display screen with the user's finger. This method includes: upon the user's touch to the display screen at a region of one of the plurality of objects being displayed, selecting the one object as a zoom target; upon an event occurring in which an intensity of the finger's touch on the display screen exceeds a predetermined threshold, determining a magnification ratio of the zoom target or a change rate of the magnification ratio, based on the intensity of the finger's touch; and zooming in the zoom target on the display screen with the determined magnification ratio or the determined change rate.

The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.

The present invention provides novel 1,3,5-triazinane-2,4,6-trione derivatives, such as compounds of any one of Formulae (I) and (II), and salts thereof, and methods of preparing the compounds. Also provided are compositions including a compound of the invention and an agent (e.g., an siRNA, mRNA, or plasmid DNA). The present invention also provides methods and kits using the compositions for delivering an agent to a subject (e.g., to the liver, spleen, or lung of the subject) or cell and for treating and / or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, liver diseases, and lung diseases.

The present invention has for its object to provide an economical cement additive capable of reducing the amount of water to be added to cement compositions and still capable of providing cement compositions with high fluidity, good processability, and a proper level of air-entraining ability resulting from sufficient foaming prevention, at low addition levels, a cement composition in which the above cement additive is used, and a polycarboxylic acid polymer excellent in dispersing effects on cement particles or inorganic powders or pigments and capable of being used with advantage as a cement additive or a dispersant for various uses.The invention provides, among others, a cement additive comprising, as main component, a polycarboxylic acid polymer (X) which has; repeating units (A), (B), (C) and (D), wherein none of the proportion of occurrence S1 of repeating unit (A) the proportion of occurrence T1 of repeating unit (B) and the proportion of occurrence E1 of repeating unit (C) is not equal to zero, the average number n of moles of an oxyalkylene group as added in repeating unit (B) is not less than 110, and that the weight average molecular weight of said polycarboxylic acid polymer is not less than 10000.

A thin film capacitor comprising an insulating substrate, a capacitor structure located on the substrate, the capacitor structure having a dielectric layer sandwiched between a lower electrode layer and an upper electrode layer, and conductor members respectively connected to the lower electrode layer and the upper electrode layer, wherein at least the dielectric layer has a side face having a sufficient slope for preventing the short circuit of the upper electrode layer with the lower electrode layer through the conductor member. A method of manufacturing such a thin film capacitor is also disclosed.

The quaternary ammonium compound described by general formula 1 below (wherein R1, R2 and R3 are the same or different hydrocarbon radicals with 1 to 4 carbon atoms, and n is an integer between 1 and 10) is used as a metal corrosion inhibitor. With this metal corrosion inhibitor, it is possible even with the addition of small quantities to adequately prevent corrosion of metal in a steam generating unit or petroleum refining or petrochemical process unit. Moreover, (β-hydroxyethyl)trimethylammonium hydroxide is used as a hydrogen chloride formation inhibitor for a crude oil atmospheric distillation unit. With this hydrogen chloride formation inhibitor, it is possible to prevent the formation of hydrogen chloride itself in a crude oil atmospheric distillation unit without having any adverse effect on the catalyst.

The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds of Formula (I) or (II), or compositions thereof, for treating or preventing a wide range of diseases (e.g., proliferative diseases (e.g., cancers, benign neoplasms, angiogenesis, inflammatory diseases, autoimmune diseases) and metabolic diseases (e.g., diabetes (e.g., type 2 diabetes, gestational diabetes)) in a subject. Treatment of a subject with a disease using a compound of Formula (I) or (II), or compositions thereof, may downregulate the expression and / or inhibit the activity of a kinase (e.g., a tyrosine kinase, such as a Tec kinase, in particular, bone marrow on X chromosome kinase (BMX)), and therefore, suppress tyrosine kinase singling in the subject.

Described herein are compounds of Formula (I)-(III), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating and / or preventing diseases are also provided.

Described herein are compounds of Formulae (I)-(II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject.

Film-forming means are coextruded to form all plastic multilayer liners and facestocks for pressure-sensitive labels, tapes, decals, signs, bumper stickers, and other products formed from sheet and roll stock. Fill means in a charge for the liner coextrusion affects stiffness and dimensional stability of the liner and / or affects the roughness of a liner face or faces. The film materials of the layers of the constructions are selected according to the cost / benefit characteristics of candidate materials considering the functional or operational requirements of the layer in question.

The present invention relates to a process for producing a skin material-laminated foamed thermoplastic resin molding and to foamed thermoplastic resin moldings, said process comprising a skin material and a thermoplastic resin foam integrally laminated with the skin material, wherein the process uses a mold comprising a male and female mold members which are mutually slidable and whose cavity clearance (t) is adjustable, the process comprising the following steps (1)-(5): (1) skin material supply step, (2) resin injection step, (3) compression step, (4) foaming step and (5) cooling and releasing step, and said moldings that are a panel-shaped foamed thermoplastic resin molding comprising a substrate and a projection standing on the substrate wherein the projection has a mean expansion ratio of not greater than 1.1 times and the substrate has a mean expansion ratio of not less than 1.3 times.

An air-fuel ratio control apparatus for an internal combustion engine, implementing integral correction of the air-fuel ratio by an integral term edfii obtained by multiplying an integrated difference between a target air fuel ratio and the actual air-fuel ratio by an integral gain, wherein the upper and lower limit values of the integral term are set based on the actual intake air amount and the actual air-fuel ratio. This limits the range of the integral term edfii to prevent it from being set at an excessively high or low level removed from the realities of the intake air amount and the air-fuel ratio, and thereby to prevent erroneous air-fuel ratio correction by the integral term.

The present invention relates to compositions and methods for preventing and treating an inflammatory disorder of a mucosa, including but is not limited to, inflammatory bowel disease and irritable bowel syndrome. More particularly, the present invention relates to compositions comprising FGF-20, a fragment, a derivative, a variant, a homolog, or an analog thereof, and their uses in preventing and treating an inflammatory disorder of a mucosa, such as inflammatory bowel disease or irritable bowel syndrome.

A yellow toner in which, in a spectral-distribution diagram in which the reflectance (%) is plotted as ordinate and the. wavelength (nm) as abscissa, the reflectance determined for a toner in a state of powder ranges from 15% to 20% at a wavelength of 500 nm and ranges from 75% to 80% at a wavelength of 600 nm, a cyan toner in which, in the like spectral-distribution diagram, the reflectance determined for a toner in a state of powder ranges from 30% to 35% at a wavelength of 450 nm and ranges from 35% to 40% at a wavelength of 475 nm, and a magenta toner in which, in the like sp.ectral-distribution diagram, the reflectance determined for a toner in a state of powder ranges from 5% to 10% at a wavelength of 425 nm and ranges from 65% to 70% at a wavelength of 675 nm. These color toners each contain corresponding pigments in specific combination, and promise color reproduction which can ensure the color tones of process inks.

The present invention provides novel compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject. (I)

Described herein are compounds of Formula (I) or Formula (VI), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I) or Formula (VI) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided.

The quaternary ammonium compound described by general formula 1 below(wherein R1, R2 and R3 are the same or different hydrocarbon radicals with 1 to 4 carbon atoms, and n is an integer between 1 and 10) is used as a metal corrosion inhibitor. With this metal corrosion inhibitor, it is possible even with the addition of small quantities to adequately prevent corrosion of metal in a steam generating unit or petroleum refining or petrochemical process unit.Moreover, (β-hydroxyethyl)trimethylammonium hydroxide is used as a hydrogen chloride formation inhibitor for a crude oil atmospheric distillation unit. With this hydrogen chloride formation inhibitor, it is possible to prevent the formation of hydrogen chloride itself in a crude oil atmospheric distillation unit without having any adverse effect on the catalyst.

A continuous flow centrifuge system is provided. The system includes a rotor, a stator, a stator housing, upper and lower bearing plates, upper and lower bearings, first and second snap rings, and lip seal. The upper bearing rotatably secures a shaft of the rotor in the upper bearing plate. The first snap ring secures the upper bearing to the rotor shaft. The lip seal is over the upper bearing and forms a rotatable seal with the upper bearing plate. The second snap ring secures the lip seal to an inner diameter of the upper bearing plate. The upper and lower bearing plates are secured to the stator housing so that the rotor is operatively aligned with the stator.

The present invention provides multi-tailed lipid compounds, and salts and stereoisomers thereof, and methods of preparing the compounds. Also provided are compositions including a compound of the invention and an agent (e.g., an siRNA, mRNA, plasmid DNA, small molecule, protein, peptide). The present invention also provides methods, and kits using the compositions for delivering an agent to a subject (e.g., to the liver, spleen, or lung of the subject) or cell and for treating and / or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, immunological diseases, gastrointestinal diseases (e.g., liver diseases), respiratory diseases (e.g., lung diseases), painful conditions, psychiatric disorders, metabolic disorders, and spleen diseases.

The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject.

A three-dimensional cell culture carrier of the present invention includes a fibrous structure having a three-dimensional space for cell culture. The fibrous structure is formed of a plurality of intertangled fibers. Each of the fibers used in the fibrous structure is made of a material having a visible light transmittance of 40% or more (preferably 50% or more) when it is formed into a shape having a thickness of 3 mm. Examples of such fibers include glass fibers. The fiber has an aspect ratio of 1 or more, and a fiber diameter of 100 μm to 700 μm.

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and / or inhibit transcription in the subject.

Described herein are compounds of Formula (I) or Formula (VI), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I) or Formula (VI) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided.

An air-fuel ratio control apparatus for an internal combustion engine, implementing integral correction of the air-fuel ratio by an integral term edfii obtained by multiplying an integrated difference between a target air fuel ratio and the actual air-fuel ratio by an integral gain, wherein the upper and lower limit values of the integral term are set based on the actual intake air amount and the actual air-fuel ratio. This limits the range of the integral term edfii to prevent it from being set at an excessively high or low level removed from the realities of the intake air amount and the air-fuel ratio, and thereby to prevent erroneous air-fuel ratio correction by the integral term.

The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.

A continuous flow centrifuge system is provided. The system includes a rotor, a stator, a stator housing, upper and lower bearing plates, upper and lower bearings, first and second snap rings, and lip seal. The upper bearing rotatably secures a shaft of the rotor in the upper bearing plate. The first snap ring secures the upper bearing to the rotor shaft. The lip seal is over the upper bearing and forms a rotatable seal with the upper bearing plate. The second snap ring secures the lip seal to an inner diameter of the upper bearing plate. The upper and lower bearing plates are secured to the stator housing so that the rotor is operatively aligned with the stator.

The present invention relates to compositions and methods for preventing and treating a disease (e.g., a joint disease, ischemic stroke, hemorrhagic stroke, trauma, spinal cord damage, heavy metal or toxin poisoning, or neurodegenerative diseases). More particularly, the present invention provides methods for preventing and / or treating a disease (e.g., a joint disease, ischemic stroke, hemorrhagic stroke, trauma, spinal cord damage, heavy metal or toxin poisoning, or neurodegenerative diseases) by using compositions comprising FGF-20, a fragment, a derivative, a variant, a homolog, or an analog thereof.